Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma-Reference-Cited by-同舟云学术

Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma

Published:2023-12-12 Issue:1 Volume:119 Page:50-61
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Onishi Akio,Matsumura-Kimoto Yayoi,Mizutani Shinsuke,Isa Reiko,Fujino Takahiro,Tsukamoto Taku,Miyashita Akihiro,Okumura Keita,Nishiyama Daichi,Hirakawa Koichi,Shimura Kazuho,Kaneko Hiroto,Kiyota Miki,Kawata Eri,Takahashi Ryoichi,Kobayashi Tsutomu,Uchiyama Hitoji,Uoshima Nobuhiko,Nukui Yoko,Shimura Yuji,Inaba Tohru,Kuroda Junya^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03680-1.pdf

Reference31 articles.

1. Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune response to SARS-CoV-2 vaccines. Biomedicines. 2022;10(7):1464. https://doi.org/10.3390/biomedicines10071464.

2. Federico M. How Do Anti-SARS-CoV-2 mRNA vaccines protect from severe disease? Int J Mol Sci. 2022;23(18):10374. https://doi.org/10.3390/ijms231810374.

3. Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79–86. https://doi.org/10.3324/haematol.2012.067272. (Epub 2012 Jul 6).

4. Sugiyama A, Kurisu A, Nagashima S, Hando K, Saipova K, Akhmedova S, et al. Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Sci Rep. 2022;12(1):16294. https://doi.org/10.1038/s41598-022-20747-x.

5. Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, et al. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clin Infect Dis. 2022;75(11):1971–9. https://doi.org/10.1093/cid/ciac292.